People taking adalimumab (Humira) for moderate-to-severe hidradenitis suppurativa (HS) saw better results across the board when the drug was combined with a surgical intervention. That's according to ...

Adalimumab in conjunction with surgery demonstrated more clinical effectiveness and improved quality of life in patients with hidradenitis suppurativa (HS) compared with outcomes in those treated with ...

Please provide your email address to receive an email when new articles are posted on . Patients achieved a reduction of 19.1 in HS severity when treated with combined surgery vs. a reduction of 7.8 ...

Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients with hidradenitis suppurativa, post hoc analysis of the PIONEER I and II ...

Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the ...

"Adalimumab, regardless of HiSCR responder status, was associated with improvements in common hematologic abnormalities," the authors wrote, adding that "these findings highlight the high inflammatory ...

Yuflyma (adalimumab-aaty) and its unbranded version may now be prescribed for HS in patients 12 years and older and for UV in children 2 years and older. The Food and Drug Administration (FDA) has ...

This retrospective study showed that anti–interleukin-17 drug secukinumab yielded favorable results in a small group of patients with severe hidradenitis suppurativa (HS). Researchers of a new study ...

INCHEON, South Korea, Oct. 17, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved expanded indications for YUFLYMA® (adalimumab-aaty) ...